Fig. 6: SNX1.3 inhibits RTK driven 2D cell migration.
From: Sorting nexin-dependent therapeutic targeting of oncogenic epidermal growth factor receptor
BT20 triple negative breast cancer cells were treated with either cSNX1.3, PTD4 control or vehicle (water) and either EGF-, Neuregulin-1 (NRG), Hepatic Growth Factor (HGF), or hyaluronic acid (HA)-induced migration on plastic was allowed for 12 h. Area migrated was measured with ImageJ.
